SCHEMBL40667

SCHEMBL40667

COc1ccc([C](c2ccc(OC)cc2)c2ccc3ccc4cccc5ccc2c3c45)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.41
ALDH1A1 P00352 4/20 0.41
HPGD P15428 2/20 0.41
HSD17B10 Q99714 2/20 0.41
KDM4E B2RXH2 2/20 0.41
CYP1A2 P05177 2/20 0.41
GLA P06280 1/20 0.41
POLB P06746 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP3A4 P08684 1/20 0.41
TSHR P16473 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
NPC1 O15118 4/20 0.40
RAB9A P51151 4/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MEN1 O00255 3/20 0.39
GAA P10253 2/20 0.39
MAPT P10636 2/20 0.39
CASP3 P42574 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6440247 0.85 NPC1 (0.51) KMT2AALDH1A1HPGDHSD17B10KDM4E
SCHEMBL8445404 0.82 ALDH1A1 (0.48) KMT2AALDH1A1HPGDHSD17B10KDM4E
SCHEMBL6750240 0.79 RAB9A (0.54) KMT2AALDH1A1HPGDKDM4EPOLB
SCHEMBL6437739 0.78 NPC1 (0.57) KMT2AALDH1A1HPGDCYP1A2CYP2D6
SCHEMBL383491 0.76 RAB9A (0.51) KMT2AALDH1A1HPGDKDM4EPOLB
SCHEMBL6457317 0.75 CYP11B1 (0.47) KMT2AALDH1A1HPGDKDM4ECYP1A2
SCHEMBL6302225 0.73 NPC1 (0.55) KMT2AALDH1A1HPGDKDM4ECYP1A2
SCHEMBL28203235 0.72 ALDH1A1 (0.44) KMT2AALDH1A1HPGDHSD17B10KDM4E
SCHEMBL1538693 0.70 ALDH1A1 (0.53) KMT2AALDH1A1HPGDHSD17B10KDM4E
SCHEMBL248050 0.70 ALDH1A1 (0.46) KMT2AALDH1A1HPGDHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 581 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3063164-B1 SYNTHETIC ROUTE TO 2'-DEOXY-2',2'-DIFLUOROTETRAHYDROURIDINES OTSUKA PHARMA CO LTD (JP) 2018-12-05 EP claimed
EP-2727915-B1 Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof CONCERT PHARMACEUTICALS INC (US) 2016-04-13 EP claimed
EP-2727915-A1 Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof Concert Pharmaceuticals Inc. (US) 2014-05-07 EP claimed
WO-2009086192-A1 BIODEGRADABLE PHOSPHATE PROTECTED NUCLEOTIDE DERIVATIVES AND THEIR USE AS CANCER, ANTI VIRAL AND ANTI PARASITIC AGENTS ALIOS BIOPHARMA, INC. (US) 2009-07-09 WO claimed
WO-2009086201-A1 2-5A ANALOGS AND THEIR USE AS ANTI-CANCER, ANTI-VIRAL AND ANTI- PARAS ITI C AGENTS ALIOS BIOPHARMA, INC. (US) 2009-07-09 WO claimed
US-7202264-B2 Supports such as glass and styrene polymers functionalized with tricyclic hetercyclic anhydrides and imides, used in the preparation of oligonucleotides ISIS PHARMACEUTICALS, INC. (US) 2007-04-10 US claimed
WO-2006117556-A2 MATERIALS AND METHODS FOR THE PHOTODIRECTED SYNTHESIS OF OLIGONUCLEOTIDE ARRAYS THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2006-11-09 WO claimed
US-20060014943-A1 Process for the synthesis of pyrazolopyrimidines EPOCH BIOSCIENCES, INC. (US) 2006-01-19 US claimed
US-6962991-B2 Process for the synthesis of pyrazolopyrimidines EPOCH BIOSCIENCES, INC. (US) 2005-11-08 US claimed
US-20050208588-A1 Supports for oligomer synthesis ISIS PHARMACEUTICALS, INC. (US) 2005-09-22 US claimed
US-20040191824-A1 Process for the synthesis of pyrazolopyrimidines EPOCH BIOSCIENCES, INC. 2004-09-30 US claimed
US-20030078413-A1 Process for the synthesis of pyrazolopyrimidines EPOCH BIOSCIENCES, INC. 2003-04-24 US claimed
WO-2024148274-A1 COMPLEMENT INHIBITION APELLIS PHARMACEUTICALS, INC. (US) 2024-07-11 WO disclosed
WO-2024145435-A2 LIPID COMPOSITIONS AND METHODS FOR DELIVERY TO IMMUNE CELLS Life Technologies Corporation (US) 2024-07-04 WO disclosed
EP-4381070-A2 CHEMICALLY MODIFIED OLIGONUCLEOTIDES Phio Pharmaceuticals Corp. (US) 2024-06-12 EP disclosed
CN-114736219-B Antitumor compounds 法马马有限公司 2024-06-07 CN disclosed
EP-0938475-A1 PIPERIDINE COMPOUNDS GILEAD SCIENCES, INC. (US) 1999-09-01 EP disclosed
WO-1998046602-A1 ALKALOID HALIDE SALTS OF SWAINSONINE AND METHODS OF USE GLYCODESIGN INC. (CA) 1998-10-22 WO disclosed
WO-1998017647-A1 PIPERIDINE COMPOUNDS GILEAD SCIENCES, INC. (US) 1998-04-30 WO disclosed
WO-1997026873-A1 ANTIMICROBIAL AURONE DERIVATIVES PHYTERA, INC. (US) 1997-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078413-A1 Process for the synthesis of pyrazolopyrimidines DPYD, PNP, UMPS KMT2A 2128/4885ALDH1A1 1288/4885HPGD 1909/4885
US-20060014943-A1 Process for the synthesis of pyrazolopyrimidines DPYD, PNP, UMPS KMT2A 2128/4885ALDH1A1 1288/4885HPGD 1909/4885
US-20050208588-A1 Supports for oligomer synthesis ILK, NOP2, PFAS KMT2A 2924/4885ALDH1A1 4121/4885HPGD 2976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.